Urology
Volume 54, Issue 6 , Pages 1022-1027 , December 1999

Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA

This study was presented in part at the 32nd Annual Meeting of the Society for Epidemiologic Research, Baltimore, Maryland, June 10 to 12, 1999.

  • Leslie A Kalish

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts, USA
    • Corresponding Author InformationReprint requests: Leslie A. Kalish, Sc.D., New England Research Institutes, 9 Galen Street, Watertown, MA 02472
    • ,
  • John B McKinlay

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts, USA

Received 7 May 1999 ,Revised 30 June 1999 ,Accepted 30 June 1999.

References 

  1. Catalona WJ, Smith DS, Ratliff TL, et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161
  2. Oesterling JE. Prostate-specific antigen (a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate). J Urol. 1991;145:907–923
  3. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al.  Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445–1449
  4. Garnick MB, Fair WR. Prostate cancer (emerging concepts, part I). Ann Intern Med. 1996;125:118–125
  5. Beduschi MC, Oesterling JE. Percent free prostate-specific antigen (the next frontier in prostate-specific antigen testing). Urology. 1998;51:98–109
  6. Bangma CH, Rietbergen JB, Kranse R, et al.  The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer. J Urol. 1997;157:2191–2196
  7. Catalona WJ, Partin AW, Slawin KM, et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation from benign prostatic disease (a prospective multicenter clinical trial). JAMA. 1998;279:1542–1547
  8. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol. 1993;150:1837–1839
  9. Oesterling JE, Jacobsen SJ, Chute CG, et al.  Serum prostate-specific antigen in a community-based population of healthy men (establishment of age-specific reference ranges). JAMA. 1993;270:860–864
  10. Anderson JR, Strickland D, Corbin D, et al.  Age-specific reference ranges for serum prostate-specific antigen. Urology. 1995;46:54–57
  11. Bangma CH, Kranse R, Bleijenberg BG, et al.  The value of screening tests in the detection of prostate cancer. (Part II: retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density). Urology. 1995;46:779–784
  12. Dalkin BL, Ahmann FR, Kopp JB, et al.  Derivation and application of upper limits for prostate specific antigen in men aged 50–74 years with no clinical evidence of prostatic carcinoma. Br J Urol. 1995;76:346–350
  13. Osterling JE, Jacobsen SJ, Klee GG, et al.  Free, complexed and total serum prostate specific antigen (the establishment of appropriate ranges for their concentrations and ratios). J Urol. 1995;154:1090–1095
  14. DeAntoni EP, Crawford ED, Oesterling JE, et al.  Age- and race-specific references ranges for prostate-specific antigen from a large community-based study. Urology. 1996;48:234–239
  15. Lin WY, Gu CJ, Kao CH, et al.  Serum prostate-specific antigen in healthy Chinese men (establishment of age-specific reference ranges). Neoplasma. 1996;43:103–105
  16. Morgan TO, Jacobsen SJ, McCarthy WF, et al.  Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med. 1996;335:304–310
  17. Kao C. Age-related free PSA, total PSA and free PSA/total PSA ratios (establishment of reference ranges in Chinese males). Anticancer Res. 1997;17:1361–1365
  18. Löfman O, Lindahl T, Varenhorst E. Age-specific reference values for serum prostate-specific antigen in a community-based population of healthy Swedish men. Scand J Clin Lab Invest. 1997;57:225–232
  19. Lein M, Koenig F, Jung K, et al.  The percentage of free prostate specific antigen is an age-independent tumor marker for prostate cancer (establishment of reference ranges in a large population of healthy men). Br J Urol. 1998;82:231–236
  20. Catalona WJ, Hudson MA, Scardino PT, et al.  Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer (receiver operating characteristic curves). J Urol. 1994;152:2037–2042
  21. Bosch JLH, Hop WCJ, Bangma CH, et al.  Prostate specific antigen in a community-based sample of men without prostate cancer (correlations with prostate volume, age, body mass index, and symptoms of prostatism). Prostate. 1995;27:241–249
  22. el-Galley RE, Petros JA, Sanders WH, et al.  Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology. 1995;46:200–204
  23. Borer JG, Sherman J, Solomon MC, et al.  Age specific prostate specific antigen references ranges (population specific). J Urol. 1998;159:444–448
  24. Feldman HA, Johannes CB, McKinlay JB, et al.  Low dehydroepiandrosterone sulfate and heart disease in middle-aged men (cross-sectional results from the Massachusetts Male Aging Study). Ann Epidemiol. 1998;8:217–228
  25. Longcope C, Goldfield SRW, Brambilla DJ, et al.  Androgens, estrogens, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab. 1990;71:1442–1446
  26. Darson MF, Pacelli A, Roche P, et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma (a novel prostate cancer marker). Urology. 1997;49:857–862
  27. Pannek J, Partin AW. Prostate-specific antigen (what’s new in 1997). Oncology. 1997;11(Huntingt):1273–1279
  28. StataCorp: Stata Reference Manual Release 5. vol 3. College Station, Texas, Stata Corporation, 1997, pp 94–104.
  29. Green PJ, Silverman BW. In: Nonparametric Regression and Generalized Linear Models. London: Chapman and Hall; 1994;p. 11–12
  30. Efron B, Tibshirani RJ. In: An Introduction to the Bootstrap. New York: Chapman and Hall; 1994;p. 45–49
  31. Ries LAG, Kosary CL, Hankey BF, et al (Eds): SEER Cancer Statistics Review, 1973–1994. NIH Publication No. 97-2789. Bethesda, National Cancer Institute, 1997, p 394.

☆ This investigation was supported by grant DK-51345 awarded by the National Institute of Diabetes and Digestive and Kidney Diseases.

PII: S0090-4295(99)00349-0

Urology
Volume 54, Issue 6 , Pages 1022-1027 , December 1999

Article Tools

* Image Usage & Resolution